Variables | Univariable: HR (95% CI) | P value | Adjusted: HR (95% CI) | P value |
---|---|---|---|---|
Population-based | ||||
MDRD4 | ||||
Categorical | 0.001 | 0.046 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 0.818 (0.382–1.751) | 0.605 | 0.799 (0.370–1.726) | 0.568 |
Stage 3a: 45–59 | 1.908 (0.790–4.609) | 0.151 | 1.423 (0.563–3.597) | 0.456 |
Stage 3b/4/5: < 45 | 4.624 (1.644–13.008) | 0.004 | 3.004 (0.976–9.247) | 0.055 |
CKD-EPI | ||||
Categorical | <0.001 | 0.019 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 2.471 (0.752–8.117) | 0.136 | 2.007 (0.607–6.640) | 0.254 |
Stage 3a: 45–59 | 4.968 (1.400–17.635) | 0.013 | 3.122 (0.851–11.456) | 0.086 |
Stage 3b/4/5: < 45 | 11.207 (2.967–42.335) | <0.001 | 6.426 (1.610–25.652) | 0.008 |
CG-BSA | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.367 (0.459–4.070) | 0.574 | 1.078 (0.360–3.230) | 0.894 |
Stage 3a: 45–59 | 3.658 (1.226–10.915) | 0.020 | 2.393 (0.787–7.275) | 0.124 |
Stage 3b/4/5: < 45 | 9.562 (3.131–29.199) | <0.001 | 5.347 (1.665–17.170) | 0.005 |
Cardiovascular risk | ||||
MDRD4 | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.008 (0.682–1.489) | 0.969 | 1.096 (0.740–1.624) | 0.647 |
Stage 3a: 45–59 | 1.682 (1.130–2.504) | 0.010 | 1.924 (1.285–2.881) | 0.001 |
Stage 3b/4/5: < 45 | 4.308 (2.844–6.526) | <0.001 | 5.138 (3.361–7.857) | <0.001 |
CKD-EPI | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.292 (0.823–2.029) | 0.266 | 1.391 (0.884–2.190) | 0.154 |
Stage 3a: 45–59 | 2.263 (1.436–3.566) | <0.001 | 2.543 (1.605–4.029) | <0.001 |
Stage 3b/4/5: < 45 | 5.397 (3.393–8.583) | <0.001 | 6.292 (3.923–10.091) | <0.001 |
CG-BSA | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.347 (0.911–1.990) | 0.135 | 1.504 (1.009–2.241) | 0.045 |
Stage 3a: 45–59 | 2.927 (1.986–4.315) | <0.001 | 3.416 (2.290–5.094) | <0.001 |
Stage 3b/4/5: < 45 | 6.277 (4.227–9.322) | <0.001 | 7.520 (4.981–11.353) | <0.001 |
Heart failure | ||||
MDRD4 | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.076 (0.643–1.800) | 0.781 | 1.016 (0.605–1.706) | 0.952 |
Stage 3a: 45–59 | 1.791 (1.066–3.007) | 0.028 | 1.517 (0.896–2.569) | 0.121 |
Stage 3b/4/5: < 45 | 3.298 (2.007–5.420) | <0.001 | 2.824 (1.704–4.680) | <0.001 |
CKD-EPI | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 2.194 (1.008–4.774) | 0.048 | 2.248 (1.030–4.906) | 0.042 |
Stage 3a: 45–59 | 2.997 (1.372–6.549) | 0.006 | 2.871 (1.306–6.310) | 0.009 |
Stage 3b/4/5: < 45 | 6.557 (3.070–14.006) | <0.001 | 5.784 (2.692–12.430) | <0.001 |
CG-BSA | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 3.243 (1.164–9.031) | 0.024 | 3.457 (1.240–9.642) | 0.018 |
Stage 3a: 45–59 | 5.266 (1.915–14.485) | 0.001 | 5.078 (1.838–14.024) | 0.002 |
Stage 3b/4/5: < 45 | 12.388 (4.595–33.398) | <0.001 | 11.006 (4.066–29.793) | <0.001 |
Post-myocardial infarction | ||||
MDRD4 | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.243 (1.115–1.385) | <0.001 | 1.296 (1.162–1.446) | <0.001 |
Stage 3a: 45–59 | 2.253 (2.014–2.521) | <0.001 | 2.251 (2.009–2.523) | <0.001 |
Stage 3b: 30–45 | 3.692 (3.276–4.162) | <0.001 | 3.509 (3.104–3.967) | <0.001 |
Stage 4/5: < 30 | 5.509 (4.591–6.610) | <0.001 | 5.076 (4.208–6.123) | <0.001 |
CKD-EPI | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.363 (1.214–1.531) | <0.001 | 1.427 (1.269–1.603) | <0.001 |
Stage 3a: 45–59 | 2.430 (2.158–2.736) | <0.001 | 2.442 (2.165–2.754) | <0.001 |
Stage 3b: 30–45 | 3.976 (3.516–4.497) | <0.001 | 3.852 (3.396–4.368) | <0.001 |
Stage 4/5: < 30 | 6.098 (5.193–7.160) | <0.001 | 5.765 (4.887–6.800) | <0.001 |
CG-BSA | ||||
Categorical | <0.001 | <0.001 | ||
Stage 1: ≥ 90 | Reference | Reference | ||
Stage 2: 60–89 | 1.302 (1.154–1.470) | <0.001 | 1.369 (1.213–1.546) | <0.001 |
Stage 3a: 45–59 | 2.447 (2.169–2.761) | <0.001 | 2.523 (2,234–2.849) | <0.001 |
Stage 3b: 30–45 | 4.230 (3.744–4.780) | <0.001 | 4.239 (3.745–4.799) | <0.001 |
Stage 4/5: < 30 | 6.536 (5.578–7.659) | <0.001 | 6.639 (5.649–7.802) | <0.001 |